{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:01:17Z","timestamp":1784246477819,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18ZR1407600"],"award-info":[{"award-number":["18ZR1407600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clbc.2019.07.013","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T19:54:34Z","timestamp":1566590074000},"page":"e65-e74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers"],"prefix":"10.1016","volume":"20","author":[{"given":"Ruohong","family":"Shui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuane","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2019.07.013_bib1","series-title":"WHO Classification of Tumors of the Breast","author":"Lakhani","year":"2012"},{"key":"10.1016\/j.clbc.2019.07.013_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clbc.2019.07.013_bib3","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib4","first-page":"237","article-title":"Guideline for testing of estrogen and progesterone receptors in breast cancer","volume":"44","year":"2015","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.clbc.2019.07.013_bib5","first-page":"262","article-title":"Guidelines for HER2 detection in breast cancer, the 2014 version","volume":"43","year":"2014","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.clbc.2019.07.013_bib6","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/jcp.53.9.688","article-title":"Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening","volume":"53","author":"Rhodes","year":"2000","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2019.07.013_bib8","first-page":"222","article-title":"Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas: concordance with biochemical assay and prognostic significance","volume":"3","author":"de Mascarel","year":"1995","journal-title":"Appl Immunohistochem"},{"key":"10.1016\/j.clbc.2019.07.013_bib9","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"Dunnwald","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2019.07.013_bib10","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor\u2013positive phenotype","volume":"25","author":"Rakha","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib11","first-page":"219","article-title":"Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: a correlative study of 942 cases","volume":"4","author":"MacGrogan","year":"1996","journal-title":"Appl Immunohistochem"},{"key":"10.1016\/j.clbc.2019.07.013_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1245\/s10434-012-2588-8","article-title":"Effect of ASCO\/CAP guidelines for determining ER status on molecular subtype","volume":"20","author":"Deyarmin","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib14","first-page":"156","article-title":"A\u00a0majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors","volume":"5","author":"Prabhu","year":"2014","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clbc.2019.07.013_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.clbc.2019.07.013_bib16","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","article-title":"HER-2 testing in breast cancer using parallel tissue-based methods","volume":"291","author":"Yaziji","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2019.07.013_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2019.07.013_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00428-011-1132-8","article-title":"Quality assessment of HER2 testing by monitoring of positivity rates","volume":"459","author":"Choritz","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clbc.2019.07.013_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/modpathol.2016.164","article-title":"Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany","volume":"30","author":"R\u00fcschoff","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2019.07.013_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ajco.12514","article-title":"Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: results from a large, multicountry study","volume":"12","author":"Pathmanathan","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clbc.2019.07.013_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-13-615","article-title":"Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study","volume":"13","author":"Varga","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2019.07.013_bib22","first-page":"43","article-title":"Is there any concordance between of IHC with FISH in HER2-positive breast cancer patients?","volume":"11","author":"Payandeh","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.clbc.2019.07.013_bib23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ajcp\/aqw224","article-title":"Her2\/neu status determination in breast cancer: a single institutional experience using a dual-testing approach with immunohistochemistry and fluorescence in situ hybridization","volume":"147","author":"Solomon","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2019.07.013_bib24","first-page":"296","article-title":"Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology","volume":"41","author":"Ying","year":"2012","journal-title":"Zhonghua Bing Li Xue Za Zhi"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919306603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820919306603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:32Z","timestamp":1761513512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820919306603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1526820919306603"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2019.07.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2019.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}